Pacific Biosciences of California (PACB) 2022年年度报告「NASDAQ」.pdf

1、2022 ANNUAL REPORTFellow Stockholders,When I joined PacBio in late 2020,I worked with our team to develop a new strategic plan to drive our growth.The first phase of that plan,setting the foundation,is primarily comprised of three components:expanding our commercial footprint to increase Sequel IIe

2、placements,innovating to create higher throughput sequencing platforms,and collaborating to demonstrate the power of HiFi,our long-read sequencing technology.Im pleased to report that despite an extremely challenging macroeconomic environment,we have made significant progress on all three strategic

3、core pillars.Before we review some of the accomplishments in 2022,I want to recognize the nearly 800 employees of PacBio whose efforts are pushing us toward our mission of enabling the power of genomics to improve human health.Their focus on innovation and collaborating with our customers has transf

4、ormed our company.Our investment in expanding the commercial organization is driving returns.In 2022,we grew the Sequel II/IIe installed base by 37%.As a result,we entered 2023 with an installed base of more than 500 units,making Sequel II/IIe the most successful sequencer in our history.Importantly

5、,we added approximately 60 brand-new instrument customers in the period and had record consumable revenue of$60 million.Second,we continued to drive innovation by launching several new products focused on the end-to-end sequencing workflow.This included innovations in our sample preparation methods

6、to lower DNA input requirements,developing automation capabilities to enable higher throughput,and delivering new software tools that allow our customers to extract more insight from their sequencing results.These improvements to our workflow set the stage for the announcement of the Revio and Onso